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1. Introduction 
Breast cancer is the most common non-skin cancer and the second leading cause of cancer 
death in women. Despite advances in the adjuvant treatment of early stage disease, many 
women will have breast cancer relapse that often is not amenable to complete surgical 
excision [Eubank et al., 2005]. There are 40,000 women per year dying of breast cancer in the 
United States, and most breast cancer victims die of progressive metastatic disease.  
Currently, the detection and staging of breast cancer involves physical examination, fine 
needle aspiration (FNA) biopsy and imaging methods, namely mammography, 
ultrasonography, breast magnetic resonance imaging (MRI) and scintimammography. 
Screening mammography is widely available and evaluates patients with low cost, yet it 
bears a sensitivity ranging from 45% to 90% and low specificity, especially in cases of dense 
breasts, fibrocystic change and scars. Ultrasonography differentiates cystic from solid 
masses. Scintimammography by the use of various common radiotracers such as 
technetium-99m hexakis 2-methoxyisobutyl isonitrile (99mTc-sestamibi), 99mTc-6,9-bis (2-
ethoxyethyl)-3, 12-dioxo-6, 9-diphosphatetradecane (99mTc-tetrofosmin), thallium-201 
chloride (201TlCl), 99mTc-methylene diphosphonate (99mTc-MDP) and pentavalent 99mTc-
dimercaptosuccinic acid [99mTc(V)-DMSA], constitutes not only a complementary modality, 
but a significant method of choice in particular clinical settings, as summarized in Table 1. 
Nuclear medicine methods enormously contribute to breast cancer clinical management due 
to the following reasons: (a) the recent technological advance in the detection and 
processing systems. Single photon emission computed tomography (SPECT) is 
progressively used more often in parallel with traditional planar scintigraphy with 
considerable improvement of the resolution and sensitivity of the scintigraphic image, 
mainly pertaining to lymph node involvement. The detection limit regarding malignant 
lesions approaches the corresponding one obtained by traditional radiological methods. 
Another important innovative improvement is positron emission tomography (ΡΕΤ), a 
technique which is based on the use of precursor metabolites (amino acids, hormones, 
monosaccharites), which are labelled with isotopes with very short half life that emit 
positrons. The pioneer characteristics of this technique enable the study of tumor biology 
accurately and non-invasively, providing interesting perspectives for research and clinical 
applications. PET is gradually used more extensively in oncology and seems to have 
particular value in breast cancer; (b) the introduction of new radiotracers has allowed the 
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acquisition of images reflecting on biological and functional parameters that can 
characterize specific tumor features, like perfusion, mitotic and metabolic activity and 
receptor status. The significance of these parameters lies upon the fact that apart from 
defining the extent of the disease, they could also be regarded as prognostic indices of 
response to treatment and tumor behavior, and thus have major impact on designing and 
monitoring local and systemic therapy. Among the developed radiopharmaceuticals, the 
tracers described in Table 2 may play significant role in investigating breast cancer, with 
particular detection accuracy. 
 
Traditional established indications 
High-risk patients with difficult mammographic evaluation  
(dense breasts, breast structural abnormalities, implants) 
Patients with multiple suspicious lesions or calcifications 
Lobular carcinoma  
Scars from previous biopsy visible on mammography 
Palpable breast mass, not detectable by mammography or ultrasound staging 
Evaluation of response to pre-operative chemotherapy 
Detection of residual disease following mastectomy 
Patients with palpable axillary lymph nodes with unknown primary focus 
Novel clinical applications for 99mTc(V)-DMSA [Papantoniou et al., 2006-2011] 
Patients with potentially premalignant mammary conditions (pre- and post-
chemopreventive treatment) 
Patients with increased serum CGRP  
Selection of patients with metastatic breast cancer for treatment with 188Re(V)-DMSA   
Table 1. Indications for scintimammography 
 
Nuclear medicine modality Radiopharmaceuticals
Scintimammography: tumor-seeking tracers 
with specific metabolic features 
99mTc-sestamibi, 99mTc-tetrofosmin, 
201ΤlCl 
Scintimammography: tumor-seeking tracer 
with proliferation-seeking properties 
99mTc(V)-DMSA [Papantoniou et al., 
Denoyer et al., Al Scheidauer et al.] 
Hydroxyapatite crystals/amorphous calcium 
phosphate-seeking scintigraphy  
99mTc-MDP 
Lymphoscintigraphy 99mTc-labelled nanocolloids 
Radioimmunoscintigraphy Labelled monoclonal antibodies 
Receptor scintigraphy  Labelled peptides with affinity for 
specific receptors 
PET 18F-FDG* 
*18F-FDG: fluorine-18 fluorodeoxyglucose 
Table 2. Synopsis of nuclear medicine exams and tracers applied in breast cancer 
Furthermore, during the past few years the scintigraphic recognition of mammary lesions 
retaining a considerable potential to progress to breast cancer has been introduced in 
association with risk factors  involved in the carcinogenic process such as breast density 
(BD) and calcitonin gene-related peptide (CGRP) [Papantoniou et al. 2010b, 2011]. 
www.intechopen.com
 
Scintimammography - Molecular Imaging: Value and New Perspectives with 
99m
Tc(V)-DMSA 
 
63 
Specifically, 99mTc(V)-DMSA scintimammography in combination with mammography may 
substantially contribute toward the visualization of these lesions [Papantoniou et al. 2005-
2007, 2010, 2011]. 
Considering that besides cytotoxic chemotherapy, various systemic options including 
hormonal and other biologically targeted therapies are now available, the detection 
potential of the imaging modalities currently employed at such early premalignant stages, is 
limited.  Therefore, this review focuses on current and future applications of traditional 
scintimammography (planar and SPECT) and PET to breast cancer, highlighting the 
significant advantages, the clinically crucial role and the perspectives of molecular imaging 
by 99mTc(V)-DMSA scintimammography. 
2. Scintimammography - molecular imaging 
2.1 Scintimammography with γ-emitting tumor-avid agents 
99mTc-sestamibi and 99mTc-tetrofosmin are lipophilic cations which accumulate in the cell and 
in mitochondria due to the negative transmembrane potential. This happens mainly in cells 
with high-energy metabolism (and hence rich in mitochondria), including neoplastic cells. 
99mTc-sestamibi imaging of breast cancer was first reported in a patient under investigation 
due to myocardial infarction  [Chiti A et al., 1994]. As opposed to 99mTc-sestamibi, 99mTc-
tetrofosmin mostly localizes within the cytosol, with only a fraction passing into the 
mitochondria. Nevertheless, considering that both tracers pass through an intact cell 
membrane, their cellular uptake and retention mainly reflects on the viability of lesion cells, 
their perfusion and their metabolic status, including cellular proliferative activity as a major 
driving force. Moreover, scintimammography using 99mTc-sestamibi/tetrofosmin is not 
influenced by mammographic limitations, like dense breast and scars. The method 
demonstrates 85-95% sensitivity and specificity regarding primary tumor imaging, although 
somewhat lower values are expected for non-palpable lesions and axillary lymph node 
invasion. In general, these two tracers present greater sensitivity than 201TlCl. The method 
can help the surgeon localize the tumor during planning biopsy or surgery. In addition, 
sestamibi is associated with prognostic significance due to the correlation between 
radiopharmaceutical uptake and tumor angiogenesis or, most importantly, between tumor 
uptake and tissue P-glycoprotein expression, which is encoded by the multi-drug resistance 
(MDR) gene. P-glycoprotein is a membrane protein that acts as an ATP-dependent drug 
efflux pump, excreting anticancer pharmaceuticals and radiopharmaceutical imaging agents 
outside the tumor cell. Thus, prediction of P-glycoprotein-mediated response to anticancer 
agents is identified in vivo by sestamibi retention or efflux. 
According to the scintimammographic protocol, the patient is asked to accommodate at 
prone position, in order for anterior, lateral and 30o posterior oblique images to be obtained. 
The latter projection is helpful for distinguishing lesions localized at the posterior breast 
segment from the ones at the thoracic wall and for axillary lesions. The planar images 
(10min/image) are acquired at 5-10 min and 60 min after intravenous (IV) injection of 740 
MBq of radiotracer activity. 
201TlCl exhibits kinetic behavior as a potassium-analogue tracer and shows intense uptake in 
all proliferating cases with increased cell number. Planar scintigraphy, including anterior 
and lateral images, takes place 3 h post IV injection of 111 MBq of the tracer. This 
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radioligand is indicated in women bearing benign or malignant breast lesions, since it 
demonstrates a sensitivity of 80-96%. Its specificity varies from relatively poor, with a false-
positive rate of 23% due to adenomas, to high (96%) in benign fibrocystic disease, which 
shows no 201TlCl uptake. Unfortunately, the tracer appears weak in detecting axillary 
metastases with a reported sensitivity of only 57%. The study seems more suitable in the 
differential diagnosis of palpable lesions, providing useful indications for the selection of 
patients for biopsy, rather than pre-operative staging [Waxmann AD et al., 1989, Lee VW et 
al., 1993]. Of note are the unfavorable radiation characteristics of this tracer when compared 
to 99mTc-labelled compounds, with increased radiation burden to the patient and inferior 
image quality. 
99mTc-methylene diphosphonate (MDP) is another radioligand applied in breast lesions and was 
first proposed by Piccolo S et al. (1995) reporting that a) in a portion of breast lesions MDP 
uptake with optimal tumor-to-background (T/Bg) ratio occurs a little after the 
radiopharmaceutical administration. This phenomenon could be attributed to the 
particularly increased tumor perfusion due to neo-angiogenesis and c) this it could be useful 
in the differential diagnosis of mammographically equivocal lesions, or in the diagnosis of 
lesions in dense breasts, in which mammography shows limited value. Protocol guidelines 
include image acquisition at anterior and posterior positions at 4 min, 10–20 min and 2 h 
post IV injection of 740 MBq of the tracer. Ninety-two percent of breast cancer lesions 
appear as a focus of 99mTc-MDP uptake in the 10–20 min-image, with mean T/Bg ratio: ~4.3, 
as opposed to the 2 h-image which is positive in 38% of cases. In addition, the method 
provides prognostic information by the traditional whole-body study identifying skeletal 
metastases. 
2.1.1 
99m
Tc(V)-DMSA scintimammography 
99mTc(V)-DMSA is a well-known tumor–seeking radiotracer with affinity for neuroendocrine 
and soft tissue tumors, such as medullary thyroid carcinoma and lung, breast, brain, and 
metastatic bone lesions [Ohta et al., 1984, Babbar et al., 1991, Kashyap et al., 1992, Hirano et 
al., 1995, Atasever et al., 1997, Lam et al., 1997, Kiratli et al., 1998, Papantoniou et al., 2002, 
2004-2007, 2010, 2011, Denoyer et al., 2004, 2005, Tsiouris et al., 2007, Al-Saeedi, 2007]. These 
tumor-seeking properties have lead to the use of 99mTc(V)-DMSA in scintimammographic 
studies. In our studies the radiotracer is prepared using a domestically available kit 
(DMS(V)/Demoscan, National Center of Physical Sciences, Institute of Radioisotopes and 
Radiodiagnostics “Demokritos”, Athens, Greece) labelled with 99mTc within our 
Department. Scintimammography is performed on a single-head gamma camera 
(Sophycamera DS7, Sopha Medical Vision International, Buc Cedex, France) equipped with 
a high-resolution, parallel-hole collimator and connected to a dedicated computer (Sophy 
NxT, Sopha Medical Vision International). The matrix is set at 256 x 256 pixels, and the 
photopeak centered at 140 keV, with a symmetric 10% window. Lateral and anterior prone 
early and late planar images (at approximately 10–20 and 60–70 minutes, respectively) are 
acquired after IV administration of 925 to 1,100 MBq tracer activity. Acquisitions are 
obtained using a special positioning pad (PBI-2 Scintimammography Pad Set, Pinestar 
Technology Inc., Greenville, PA). Breast radiotracer uptake in early and late images is first 
evaluated visually. Any focally increased accumulation is regarded as associated with 
invasive pathology, whereas any other pattern of a more widespread diffuse uptake has 
been found to correspond to pre-invasive lesions (ductal carcinoma in situ (DCIS), epithelial 
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hyperplasia) [Papantoniou et al., 2005a, 2006a]. Semiquantitative analysis is also performed. 
Radiotracer uptake area is calculated at the late (60-minute) images by drawing regions of 
interest (ROI) encompassing the total breast and the area of focally and/or diffusely 
increased tracer uptake in the lateral view; then the number of pixels within these two 
regions is divided. The aforementioned procedure is repeated in the anterior scintigraphic 
image, and the average tracer uptake area of these two views is considered the tracer uptake 
area of the breast under investigation. 
Our research over the last two decades has been increasingly focused on the behavior, 
kinetics and properties of 99mTc(V)-DMSA in a variety of breast lesions, based on the 
postulation that breast cancer is the end-result of a continuum, i.e. a pathway leading to 
malignant transformation upon which intervention possibilities may emerge and early 
avoid disease development and progression. Therefore this research was initially limited on 
evaluating invasive ductal carcinoma (IDC) and was continued backwards through the 
pathway of malignant transformation, i.e. to include DCIS and to reach even some cases of 
the early stages of epithelial hyperplasia, occasionally representing a state of a so-called 
“activated” normal epithelium, which could eventually progress to a premalignant state and 
eventulally to malignant transformation, though lacking such evidence or suspicion on any 
available imaging modality or even biopsy. Based on in vivo scintigraphic studies, we 
advocated that its cellular uptake mechanism is closely related to cellular proliferation, as 
expressed by the Ki-67 immunohistologic index [Papantoniou et al., 2004-2006] and at the 
same time is independent from estrogen receptor (ER) status [Babbar et al., 1991, Kashyap et 
al., 1992]. It has been further demonstrated that the uptake of 99mTc(V)-DMSA is related to 
cell proliferation, focal adhesion kinase (FAK) activation, neo-angiogenesis and 
overexpression of several growth factors, including CGRP and platelet-derived growth 
factor (PDGF) [Papantoniou et al., 2005-2007, 2010, 2011]. Denoyer and colleagues elucidated 
the exact mechanisms; notably, the tracer reflects phosphate ion (Pi) transport and 
metabolism, entering cancer cells specifically via the type III Na/Pi co-transporter, this 
uptake being driven by the cellular levels of phosphorylated (i.e. activated) FAK, a keystone 
of accelerated proliferation [Denoyer et al., 2004, 2005]. 
With reference to the scintimammographic diagnostic yield, we have demonstrated that in 
cases of clinical and/or mammographic suspicion, both 99mTc-sestamibi and 99mTc(V)-DMSA 
exhibit high sensitivity (88.4%), specificity (93.3%), positive predictive value (PPV) (95%), 
negative predictive value (NPV) (82% & 80%), and accuracy for the primary lesion (90 & 
89%, respectively). Notably, in lesions of less than 1 cm in diameter, the planar imaging 
sensitivity drops to ~75%, a percentage which is considerably improved by SPECT. 
Regarding lymph node involvement, the tracers have been reported to show 78.9% 
sensitivity and 86.3% specificity. Pre-invasive lesions, like DCIS and lobular carcinoma in 
situ (LCIS) are detected with high sensitivity by 99mTc(V)-DMSA, whereas with high 
specificity by 99mTc-sestamibi [Papantoniou et al., 2001, 2002]. 
Moreover, in breast cancer we have determined tumor size and Ki-67 as independent 
parameters of 99mTc-sestamibi and 99mTc(V)-DMSA uptake, respectively; hence tumors 
which accumulate 99mTc(V)-DMSA sustain increased cell proliferation and are in fact more 
aggressive [Papantoniou et al. 2002]. 
Relatively recent in vivo and in vitro studies have demonstrated that 99mTc(V)-DMSA 
possesses the potential to depict increased cellular proliferation, compatible with increased 
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Ki-67 expression, not only in IDC (Figure 1) but also in some cases of epithelial hyperplasia 
of the usual type and in pre-invasive mammary lesions like DCIS, independently of the 
presence of estrogen or progesterone receptors [Boyd et al., 1998, Papantoniou et al., 2004-
2007, Denoyer et al., 2004, 2005, Tamimi et al., 2007]. Characteristic diffuse and intense 
99mTc(V)-DMSA uptake is depicted in a case of usual ductal breast hyperplasia in Figure 2 
(a) & (b), though no corresponding findings are observed by 99mTc-sestamibi (Figure 2 (c) & 
(d)). 
 
Fig. 1. 99mTc(V)-DMSA scintimammography (lateral projections) in a 58-year-old woman 
bearing a 2.5-cm, grade III, left-sided IDC with a coexistent 5-cm DCIS, both diagnosed 
histologically. A. The round-shaped focal tracer accumulation (arrow) corresponds to the 
invasive lesion and is noticeable since the early (10-minute) acquisition. Anterior to it lies a 
restricted, hardly visible region of diffuse tracer uptake (arrowhead). B. On the contralateral 
breast, there is also a rather faint extended area of diffuse uptake (arrowheads). C. In the late 
(55-minute) image, the focal 99mTc(V)-DMSA accumulation intensifies and its margins 
expand and become less sharply demarcated from the surrounding breast (arrow). The 
diffuse tracer uptake, corresponding to the in situ component, substantially increases and 
extends above and anterior to the invasive lesion, occupying an area of the gland seemingly 
normal on early imaging. D. Likewise, the inhomogeneous diffuse uptake area on the 
normal right breast becomes clearer and expands over time. No biopsy for histologic 
confirmation was performed on this breast; nonetheless, based on our experience from 
similar histologically-verified scintimammographic patterns, the finding is suspicious of 
representing a widespread pre-invasive lesion (DCIS and/or epithelial hyperplasia) 
[Papantoniou et al., 2007]. 
At the same time, our continuing research shed light to the intensified CGRP expression and 
neoangiogenesis in IDC with a coexistent in situ and/or hyperplastic component, in 
association with the tendency of the proliferation depicter 99mTc(V)-DMSA to image pre-
invasive breast pathologies. The CGRP/99mTc(V)-DMSA correlation could be indicative of 
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Fig. 2. Dual-tracer study in usual breast hyperplasia. Usual ductal hyperplasia of the right 
breast in a 68-year-old woman. Scintimammography, right lateral projection; 99mTc(V)-DMSA 
at (a) 10 min and (b) 70 min. Diffusely increased tracer uptake in the area corresponding to the 
lesion is observed, barely visible during early acquisition (arrowheads), but clearly perceptible 
at 70 min (lesion-to-background ratios: L/Bearly =1.32 and L/Blate=1.83). 99mTc-sestamibi at (c) 
10 min and (d) 65 min. No increased tracer activity is identified in the corresponding area 
throughout the study (L/Bearly=1.12 and L/Blate =1.14). [Papantoniou et al., 2006b]. As a cell 
proliferation tracer, 99mTc(V)DMSA evaluates the invasive potential in a case of usual ductal 
breast hyperplasia, i.e. identifies mammary tissue with increased cellular proliferation, a state 
of so-called “activated” epithelium, which is related to Ki-67 expression and thus could 
provide some indication of its probability to progress towards atypical ductal hyperplasia, 
DCIS and IDC, i.e. the malignant transformation pathway upon which intervention 
possibilities may aid in early avoidance of disease development and progression. 
an additional proliferative role for CGRP, possibly exerted through the PDGF/PDGF-
receptor system. In this study, the preferential CGRP expression in low- rather than in high-
grade IDC added support to the hypothesis of its precocious role primarily during the early 
stages of mammary malignant transformation [Papantoniou et al., 2007]. 
Furthermore, in a recent retrospective study we aimed at identifying a possible relationship 
between mammographic BD and scintimammographic 99mTc(V)-DMSA uptake in various 
breast histologies. We also investigated whether women with dense breasts, possibly 
expressing a proliferative potential, could be discriminated visually or on the basis of 
semiquantitative analysis of 99mTc(V)-DMSA uptake intensity and benefit from biopsy and 
possible proper chemoprophylactic treatment. Our findings support that increased BD 
correlates with the presence of florid epithelial hyperplasia and mixed DCIS+IDC but not 
with pure IDC or mild epithelial hyperplasia. Its close relationship to the proliferation-
seeking 99mTc(V)-DMSA, which also showed an affinity to florid epithelial hyperplasia, 
indicates that stromal microenvironment may constitute a specific substrate leading to 
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progression to different subtypes of cancerous lesions (i.e. DCIS+IDC) that are totally 
different from pure IDC originating from particular pathways. 
In another prospective study of ours enrolling women with breast epithelial hyperplastic 
lesions, a relatively short (4-week) scheme of daily oral intake of the non-steroidal anti-
inflammatory drug (NSAID) ibuprofen (400 mg) resulted in the reduction of diffuse 
99mTc(V)-DMSA uptake (Figure 3) [Papantoniou et al., 2010]. Other recent studies have 
shown that cyclo-oxygenase-2 (COX-2) inhibitors may reduce the risk of breast cancer 
[Harris et al., 2006]. The biokinetic characteristics of 99mTc(V)-DMSA support our suggestion 
that the observed reduction in its uptake could be attributable to ibuprofen-induced COX 
inhibition and may indicate a “switch off” mechanism on activated FAK, rather than a 
slowing down of the proliferation rate per se. 99mTc(V)-DMSA cellular uptake is linked to 
FAK activation and cell proliferation, which is a precocious stage of malignant 
transformation [Papantoniou et al. 2004, Le Jeune et al. 2005, Al-Saeedi, 2007]. Compared to 
invasive lesions, the exact mechanism of 99mTc-(V)DMSA accumulation in benign 
proliferating diseases and in some non-proliferating diseases with higher lesion-to-
background tracer uptake ratios is not yet clear [Papantoniou et al. 2004, 2006b]. 
Nevertheless, based on the imaging properties and biokinetic characteristics of 99mTc(V)-
DMSA in relation to mammographic density and its ability to visualize potentially pre-
invasive lesions, the clinical impact of various chemopreventive agents may be evaluated by 
quantifying their effect on 99mTc(V)-DMSA breast uptake. 
 
Fig. 3. Early (A) and late (B) images of 99mTc(V)-DMSA breast distribution at baseline and 
corresponding acquisitions after a monthly oral course of ibuprofen (C and D, respectively). 
After the NSAID treatment the diffuse tracer uptake is notably diminished on both early 
and late imaging [Papantoniou et al., 2010] 
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We also studied prospectively the variation of the serum neo-angiogenic neuropeptide 
CGRP levels in women bearing histologically confirmed benign and malignant breast 
lesions and evaluated its possible correlation with mammographic BD. Among the various 
lesions, including mild, florid and atypical epithelial hyperplasia as well as DCIS and pure 
IDC, women suffering from mixed DCIS+IDC demonstrated significantly higher serum 
CGRP levels, which also correlated with BD. These findings further support that DCIS+IDC 
represents a discrete pathological entity which is evoked by an interdependent mechanism 
between BD and serum CGRP expression. In addition, in the near future serum CGRP levels 
could constitute a useful pre-operative index regarding the nature and type of a 
mammographically suspicious lesion, in order for the proper therapeutic scheme to be 
planned, and potentially for the challenging innovative perspective of introducing 
adjunctive therapeutic administration of anti-CGRP peptides. 
Finally, in advanced breast cancer stages, 99mTc(V)-DMSA uptake in metastatic lesions may 
guide therapeutic 188Re(V)-DMSA administration, as propounded by Papantoniou and 
colleagues. Currently this protocol has just started being processed in collaboration with 
Djokic and colleagues (Vince Institute of Nuclear Sciences, Belgrade, Serbia). 
2.2 Lymphoscintigraphy and lymphoimmunoscintigraphy 
The development of distant metastases and breast cancer patient survival appear to be 
related to lymphoscintigraphic positivity [Casara et al., 1992, Uren et al., 1995]. Based on the 
used radiotracers, the following techniques have been applied:  
i. Lymphoscintigraphy using labelled colloids. The used radiolabelled particles are 10-30 
nm in size, pass through the extracellular space into the lymph capillaries and are then 
transferred by the lymph to the regional lymph nodes, to be recruited by macrophages. 
The colloids used are labelled with 99mTc and include antimony/sulphur/colloids, b) 
rhenium/sulphur/microcolloids and c) albumin nanocolloids. 
Protocol guidelines indicate injection of ~37 MBq radioactivity in the extracellular space 
(intradermal, subcutaneous or submucosal) and the injection site depends on the lymph 
node region under investigation. In breast cancer, the tracer is usually injected in the 
interdigital spaces of the hand when examining axillary lymph nodes, at the periareolar 
zone when intramammary lymph nodes are studied, parasternally by the xiphoid 
process in order for the internal mammary chain to be investigated, or intercostally or 
close to the tumor. 
For over the past decade the strategic importance of the pre-operative determination of 
lymph node invasion at the mammary region has encouraged the application of 
lymphoscintigraphy using colloids for lymphatic mapping and detection of the sentinel 
lymph node (SLN) (100% PPV and 96% NPV). Lymphoscintigraphy can be successfully 
applied in breast cancer management, if conducted intra-operatively by the use of γ-
probe and in combination with blue dye; this technique can identify axillary lymph 
node invasion and through SLN detection may allow planning strategy and extent of 
the surgical operation [Krag et al., 1993, De Cicco et al., 1997]. Unfortunately, the 
method lacks adequate specificity. Therefore, particular attention has been paid to 
alternative methods:  
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ii. Lymphoscintigraphy using tumor-seeking tracers that can localize neoplastic tissue, like 
99mTc-sestamibi, which localizes invaded lymph nodes with 80% PPV and NPV; and 
iii. Lymphoimmunoscintigraphy using monoclonal antibodies (MAbs) administered 
IV, subcutaneously or directly into lymphatics [Khalkhali et al., 2001]. The first 
lymphoimmunoscintigraphic studies were performed in 1984 and since then 
various 123/131I, 111In or 99mTc-labelled MAbs have been applied, including anti-
breast MAb (131I-RCC-1), MAbs raised against human milk fat globulins (131I-anti-
HMFG1, anti-HMFG2) and anti-carcinoembryonic antigen MAbs (99mTc- or 131I-
labelled anti-CEA, 99mTc-BW 431/26) [Thompson et al., 1984, Athanassiou et al., 
1988, Kairemo., 1990]. MAbs approved by the United States Food and Drug 
Administration (FDA) include the anti-CEA and B72.3, prepared against the tumor-
associated glycoprotein- TAG-72. In most cases, breast cancer cell lines produce 
CEA, although only a slight increase of serum CEA levels above normal may 
appear [Lind et al., 1991]. Regarding the detection of lymph node breast cancer 
metastases by arcitumomab, the commercially applied kit of anti-CEA MAb (CEA-
Scan, Immunomedics, Morris Plains, NJ, USA), it has achieved 75% sensitivity, 83% 
specificity, 80% accuracy, 75% PPV and 83% NPV [Nabi, 1997, Goldenberg et al., 
1999]. The method has not gained access into routine clinical practice though, 
because false-positive results are frequent due to tracer uptake by inflammatory 
lymph nodes, the technique is relatively complex owing to the slow tracer kinetics 
and biodistribution and the radiolabelled MAbs can hardly be obtained. 
Nevertheless the inherent biologic property of MAbs to accumulate selectively in 
the tumor as well as in metastases could be useful in both imaging and treatment of 
breast cancer. Specifically, “cold” or “hot” monoclonal antibodies may be applied 
therapeutically, with or without chemotherapeutic agents, thereby propounding 
significant changes in overall breast cancer management and survival [Stipsanelli et 
al., 2005]. Hence, further research may assist in most effectively applying 
lymphoimmunoscintigraphy to aid decision upon conservative or surgical 
approach, monitoring response to treatment and evaluating treatment regimes. 
2.3 Radioimmunoscintigraphy 
Radioimmunoscintigraphy may play a major role in the diagnosis of multifocal breast 
cancer by revealing residual or recurrent tumors, and also occult metastases. Several 
labelled MAbs, already mentioned above, have been hitherto used in breast cancer and new 
immuno-substrates continue to be proposed. The c-erbB-2 (also known as HER2) oncogene 
receptor is overexpressed in 25%-30% of breast cancer cell lines and is associated with poor 
prognosis. The expression of the products of HER2 oncogene in malignant mammary tissue 
and lymph node metastases has been studied in vivo by radioimmunoscintigraphy using 
anti-c-erbB-2 oncoprotein MAb labelled with 99mTc and has been targeted by “cold” or “hot” 
synthetic therapeutic immuno-agents. Specifically, the recombinant humanized “cold” anti-
HER2 MAb (or trastuzumab) has been widely used in the United States to treat breast 
cancer, either alone or combined with chemotherapy. Moreover, radioimmunotherapy 
comprises systemically administered MAbs, linked to high-energy, beta-emitting 
radionuclides, such as yttrium-90 (90Y-BrE-3, 90Y-m170) and 131I- or 90Y-labelled L6 antibody, 
yielding partial or rarely complete responses. Adjuvant peripheral blood stem cells 
transfusion prevents myelotoxicity. 
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Scintigraphic protocol guidelines suggest planar or SPECT imaging following tracer 
administration in the extracellular space or more often IV and rarely via an alternative route 
(e.g. intraperitoneally).  
The higher PPV and NPV for anti-CEA-MAb SPECT as compared to mammography (100% 
vs 91% and 78%-80% vs 25%, respectively) allows for prompt biopsy or lumpectomy in 
MAb-positive lesions. High scintigraphic yield has also been reported for 99mTc- or 111In-
labelled m170 with 90% sensitivity, 93% specificity and 92% accuracy concerning the 
detection of both primary and metastatic breast cancer lesions measuring less than 1 cm in 
diameter [McEwan et al., 1994]. Similar results for breast cancer detection have been shown 
by the use of satumomab (OncoScint, Cytogen Corp, Princeton, NJ USA), which consists of 2 
mg of B72.3 MAb labelled with 111In [Nabi., 1997, Khalkhali I et al., 2001]. 
Overall, suggested applications of the technique do not mainly aim at diagnosing the 
primary tumor, but at identifying regional lymph node spread and distant metastases (bone 
and soft tissue), which are not otherwise visualized during pre-operative staging and at 
post-treatment follow-up. 
2.4 Receptor imaging 
Another radiopharmaceutical category of potential interest for imaging breast lesions 
comprises substances with high affinity for receptors. Receptor imaging may be applied in 
the diagnosis, staging, restaging, response to therapy and prognosis of breast cancer 
patients. Radiolabelled estradiol has been under investigation in vivo by traditional 
scintiscan (with 16-a,17-b-iodo-estradiol- 123IE2) and by PET. In patients with suspected 
breast cancer, it has shown ≥66% sensitivity. Nevertheless, differential diagnosis of a lesion’s 
benign or malignant nature is difficult to be based solely on this technique, mainly because 
fibrocystic breast disease is also characterized by ER expression [Scheidauer et al., 1991, 
Rijks et al., 1996]. 
An interesting alternative approach utilizes radiolabelled somatostatin analogues, e.g. 111In-
pentetreotide. Upon investigating 52 breast cancer patients, somatostatin receptor 
expression has been reported to reach 85% in ductal and 56% in lobular histologies; a total of 
75% detection rate regarding the primary lesion, but only 30% sensitivity for axillary lymph 
node status. Overall, despite the in vivo breast cancer somatostatin receptor depiction, the 
method is inferior to the use of traditional 99mTc-labelled scintimammographic agents, 
owing to comparatively unfavorable dosimetry and cost-effectiveness [Van Eijck et al., 
1994]. 
2.5 Other molecular metabolic imaging modalities: positron emission tomography 
(PET) 
Initial PET studies on breast cancer were performed by Beany and colleagues in 1984. They 
demonstrated that breast tumors sustain higher perfusion than normal tissues and that 
despite the increased total oxygen consumption by the neoplastic tissue, oxygen extraction 
within the tumor is significantly decreased compared to normal tissues. Later on Mintun 
and colleagues described the visualization of primary tumors and a great percentage of 
lymh node invasion by the IV injection of steroid hormones labelled with positron-emitting 
nuclides, specifically 18F-16-a fluoroestradiol (FES). Hormone receptor imaging constitutes a 
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major functional approach of PET on breast cancer research. A subsequent study revealed 
93% sensitivity for 18F-a-FES in the detection of the primary tumor, metastases or relapse. At 
the same time, clearly decreased radiotracer lesion accumulation was observed in patients 
receiving anti-estrogen treatment. Thus, the ability to estimate and evaluate 18F-a-FES 
uptake highlights the important role of PET on assessing breast cancer patients’ response to 
endocrine treatment [Flanagan et al., 1996]. On the contrary, frustrating were the first 
attempts to depict progestin receptors (PgR) using fluoro-16a-ethyl-19-norprogesterone 
(FENP) labelled with 18F. According to Dehdashti and colleagues (1991), the inherent 
radiotracer disadvantage is its non-specific uptake resulting in background uptake to the 
skeleton, normal mammary tissue and blood circulation. Other interesting PET radiotracers 
that may eventually allow for in vivo breast tumor characterization, comprise carbon-11 
methionine (11C-MET) as a tumor protein metabolism indicator; 11C-thymidine or the most 
promising 18F-fluoro-L-thymidine (FLT) as markers for cellular proliferation; 64Cu-labelled 
peptide agonists of alphavbeta3 integrin as possible markers for angiogenesis; and 18F-
fluoromisonidazole as a marker for tumor hypoxia [Khalkhali et al., 2001, Chen et al., 2004]. 
PET studies retain the major advantage of true quantification of the radiotracer distribution. 
The most widely used radiopharmaceutical in clinical PET is 18F-FDG, a tracer focusing on 
the study of tumor glucose metabolism. Protocol guidelines indicate the IV administration 
of 370 MBq of the tracer to a fasting patient (blood Glu< 200mg/dL) with concurrent 
hydration and imaging after 60-180 min. 
18F-FDG-PET applications in breast cancer patients have attempted detection, staging, and 
monitoring treatment response. According to a large series, the sensitivity for detecting 
tumors less than 1 cm is reported to be 57%, compared to 91% for tumors larger than 1 cm 
[Avril N et al., 2000]. The sensitivity for detecting carcinoma in situ appears even lower at 
25%. A significantly higher false-negative rate has been observed in infiltrating lobular 
carcinoma (ILC) compared to IDC (65% vs 24%, respectively), possibly due to a higher 
metabolic activity associated with poor prognosis. The specificity of FDG-PET in 
differentiating benign from malignant lesions approaches 90% in most of the studies, with 
the false positive results mostly attributable to inflammatory conditions. Overall sensitivity 
in the detection of the primary tumor has been reported to reach 80%-100% and specificity 
75%-100%. The verified prognostic significance of FDG uptake in the primary tumor has yet 
to be clarified with reference to the driving biochemical mechanisms evoking enhanced 
glucose metabolism. Yet, based on various research reports, its proven accuracy in detecting 
the primary tumor and axillary staging, does not surpass its most important current clinical 
application, i.e. the detection and definition of the extent of recurrent or metastatic breast 
cancer and monitoring response to treatment. FDG-PET is complementary to conventional 
staging methods in terms of higher sensitivity in identifying metastatic nodal and lytic (or 
mixed) bone lesions (95% sensitivity and specificity vs. 93% sensitivity and 79% specificity 
by conventional imaging). Regarding distant metastases, PET appears to be more accurate 
compared to conventional staging modalities, with the exception of brain and osteoblastic 
bone metastases. Nevertheless, its sensitivity and specificity ranging from 57% to 100% and 
66% to 100%, respectively in various series, PET cannot be a substitute for traditional staging 
by computed tomography (CT) and bone scintigraphy [Eubank WB et al., 2005]. The 
evaluation and follow-up of the response of metastases and locally advanced disease to 
treatment consists the mainstay of clinical PET in breast cancer. Precocious metabolic 
response, as compared to the delayed tumor size reduction, is demonstrated by FDG-PET, 
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thus permitting earlier assessment of response to neo-adjuvant chemotherapy administered 
in locally advanced disease (after 1 or 2 cycles instead of 3 to 4 required by conventional 
morphological imaging modalities). This early metabolic amendment potentially indicates 
cancer cell resistance to apoptosis [Eubank et al., 2005]. 
2.6 Developing horizons 
Small tumor size is perhaps the most significant limiting factor of conventional planar 
scintimammography. The development of small field-of-view, dedicated breast γ-cameras 
with high-resolution CdZnTe (CZT) detectors seems to contribute greatly to increasing the 
diagnostic accuracy of the modality even for lesions below the 1-cm range [Spanu et al., 
2008, 2009]. 
Limitations of FDG uptake including small tumor size, increased breast density, more well-
differentiated histologic subtypes (tubular carcinoma and CIS) and lobular carcinomas, have 
urged for technological improvements. The spatial resolution has been further enhanced 
with the introduction of the hybrid PET/CT scanner, which shows higher sensitivity and 
specificity than either PET or CT used separately. 
Dynamic contrast-enhanced CT (DCECT) can measure the regional blood flow and volume 
along with mean transit time of blood through the capillaries and thus tumor perfusion. 
Combined FDG-PET/DCECT can assess not only tumor glucose metabolism, but also tumor 
vascularity. 
These two parameters can be used in the differential diagnosis between benign and 
malignant lesions, assessment of tumor aggressiveness and prognosis, localisation of 
residual disease, treatment selection and follow-up, assessment of response to treatment and 
radiotherapy planning. 
Furthermore, since PET using Η215O for tumor perfusion evaluation is not readily available, 
the method has not entered clinical practice. Contrast-enhanced dynamic MRI and FDG-PET 
may obtain similar results, which seem advantageous over DCECT due to the lack of 
ionizing radiation and possible reactions to the IV contrast media. 
In general, the coordination of multiple methods for breast imaging is expected to improve 
detection, diagnosis and clinical management of breast cancer patients. Detection and 
diagnosis of breast cancer may be based initially on mammography. Suspicious lesions 
should be elucidated by SPECT or PET and MRI, in order to avoid unnecessary biopsies. 
While PET differentiates malignant lesions by their most enhanced metabolic activity and 
thus intense imaging, MRI provides the exact morphologic information about lesion site, 
which is required for planning biopsy or radiotherapy [Baum, 2008]. In addition, maximal 
benefit from PET and MRI may be obtained by spatial alignment and fusion in a single 
image. Difficulties resulting from the soft and easily deformed tissue may be overcome by 
using identical patient positioning and fiducial skin markers visible in both PET and MRI, 
which should be taped to predetermined locations on the skin of the breast prior to image 
acquisition. By this technique, it is posssible to estimate marker and nodule motions based 
on surface and oncometric coefficients using specific software heat transfer module.  
Another approach towards a better PET/MRI image utilizes PET/CT scanner. Synchronized 
CT and PET acquisition may permit further accuracy in corresponding breast sites in 
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conjunction with MRI skin markers. Positron emission mammography (PEM) is conducted 
by concurrent acquisition using two planar detectors and a traditional mammographic 
system and its role in screening or diagnosis still constitutes a field under investigation, 
although it does sustain the potential capability of detecting smaller and less FDG-avid 
tumors than the conventional whole-body PET. 
Finally, other SPECT or PET assessments using proper tracers may determine selection of 
treatment for breast cancer patients through: a) quantification of the therapeutic target by 
receptor imaging, radioimmunoscintigraphy and 99mTc(V)-DMSA-depicted cell proliferation 
in a CGRP-related neo-angiogenic background, introducing e.g. the ER (tamoxifen and 
letrozole), HER2 (trastuzumab [Herceptin]), EGFR (gefitinib [Iressa]) and angiogenesis 
factors (bevacizumab [Avastin]), considering that tumor expression may also be examined 
in vitro on biopsy specimens, b) identification of resistance factors, i.e. anti-HER2 MAb-
depicted HER2 expression which evokes resistance to hormone therapy, 99mTc-sestamibi-
depicted P-glycoprotein expression which denotes resistance to chemotherapy (doxorubicin, 
taxanes) and c) measurement of early response to treatment, as indicated by reduction of cell 
proliferation shown by 99mTc(V)-DMSA or 18F-FLT.  
3. Conclusion 
In the era of rapidly developing technology, improvements in mammographic and 
molecular diagnostics appear promising, keeping up with the progress and corresponding 
demands raised by therapeutic oncology. The combination of multiple imaging methods 
(PET/CT, PET/MRI etc.) may concurrently evaluate both morphological and functional 
parameters and may directly influence the clinical management of patients bearing breast 
lesions, especially in recurrent or metastatic disease.  
Scintimammography on its own is a simple, safe, non-invasive and widely available 
conventional nuclear medicine technique, which provides valuable multilevel information 
in the clinical management of breast lesions. The method visualizes the lesion site and also 
reflects specific biological and functional lesion features, including perfusion, proliferative 
potential, metabolic activity and receptor status. Thus, scintimammography represents not 
only a complementary method, but also a study of choice by applying the proper 
radioligand in the corresponding clinical background. It is noteworthy that the whole-body 
absorbed radiation dose for scintimammography is equivalent with that of mammography. 
Current innovative scintimammographic findings using 99mTc(V)-DMSA and 99mTc-
sestamibi add to our understanding of the process of malignant transformation, tumor 
biology and further propound individualized treatment strategy by improving our ability to 
depict and possibly quantify the therapeutic target, identify drug remission and resistance 
factors, measure and predict early response and possibly apply novel therapeutics such as 
188Re(V)-DMSA or anti-CGRP peptides. 
Hence, the clinical impact of the recent scintimammographic findings could be of great 
value in terms of  preoperative evaluation –on a molecular basis– of the extent and the 
nature of a suspected breast lesion, i.e. extent of the DCIS component in a mixed DCIS+IDC, 
lesion multicentricity or lymph node involvement. Furthermore, possible 
chemoprophylactic treatment with tamoxifen, aromatase inhibitors or anti-CGRP peptides 
in pre-cancerous lesions, or even prophylactic administration of NSAIDs in florid 
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hyperplastic lesions could be considered in patients with diffuse breast uptake patterns on 
99mTc(V)-DMSA. Finally, treatment with 188Re(V)-DMSA in cases of advanced disease with 
osseous and soft tissue metastatic spread could be considered if these lesions are depicted 
by breast and whole-body 99mTc(V)-DMSA scintigraphy.  
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